Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer [clinicaltrials:NCT00005053]
Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer [clinicaltrials:NCT00005053]
Bio2RDF identifier
NCT00005053
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00005053
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... cannot be removed by surgery.
brief title [clinicaltrials_vocabulary:brief-title]
Glufosfamide With or Without H ...... ith Advanced Pancreatic Cancer
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Determin ...... ll be accrued for this study.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2000-04-06T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
keyword [clinicaltrials_vocabulary:keyword]
adenocarcinoma of the pancreas
recurrent pancreatic cancer
stage III pancreatic cancer
stage IV pancreatic cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2012-09-20T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00005053
official title [clinicaltrials_vocabulary:official-title]
Open Label Phase II Study on G ...... in Advanced Pancreatic Cancer
org study id [clinicaltrials_vocabulary:org-study-id]
EORTC-16994P
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2001-03-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
EORTC-16994P
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1999-12-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2012-09-01T00:00:00Z
identifier
clinicaltrials:NCT00005053
title
Glufosfamide With or Without H ...... ith Advanced Pancreatic Cancer
@en
type
label
Glufosfamide With or Without H ...... r [clinicaltrials:NCT00005053]
@en